O-(tert-Butyldimethylsilyl)-L-homoserine, 97%, 250mg

3,5-Diamino-6-bromo-pyrazine-2-carboxylic acid, 95%, 100mg

2-Bromoacetamide, 95.0%, 5g

(5E)-2-mercapto-5-[4-(trifluoromethyl)benzylidene]-1,3-thiazol-4(5H)-one, 95.0%, 5g

Flacons à fond rond à trois cols cols latéraux parallèles, 6000 ml, 45/40, 29/32, 1 pièce

(2S,3R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-methylpentanoic acid, 95.0%, 100mg

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthalenecarboxaldehyde, 97%, 5g

2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-[4-(1-methylpropyl)phenyl]acetamide, 98%, 50mg

5-Bromo-2-pyrazinecarboxylic acid, 95.0%, 1g

(R)-tert-Butyl 1-(cyclohexanecarbonyl)pyrrolidin-3-ylcarbamate, 95.0%, 1g

3-[[3,5-Bis(trifluoromethyl)phenyl]amino]-4-[[(1R,2R)-2-(dimethylamino)cyclohexyl]amino]-3-cyclobutene-1,2-dione, 97%, 250mg

5 mm Thin Wall Precision NMR Sample Tube 7" L, 600MHz, 5x1ea

2,5-Bis(trimethylsilyl)-1,4-phenylene Bis(trifluoromethanesulfonate)>98.0%(GC)1g